What evidence exists regarding clinical outcomes of catheter ablation for atrial fibrillation in patients aged 85 years or older?

Catheter Ablation for Atrial Fibrillation in Patients ≥85 Years

Catheter ablation is a reasonable and safe treatment option for carefully selected patients with atrial fibrillation in their late 80s, demonstrating meaningful symptom improvement and quality of life benefits despite higher AF recurrence rates compared to younger patients.

Guideline Framework

Current major guidelines support catheter ablation for AF but do not specifically exclude very elderly patients. The 2024 ESC guidelines 1 recommend catheter ablation as second-line therapy after antiarrhythmic drug failure, or as first-line for paroxysmal AF, with the primary indication being reduction in AF-related symptoms and quality of life improvement. The 2023 ACC/AHA/ACCP/HRS guidelines 2 have upgraded catheter ablation to Class 1 indication as first-line therapy in selected patients, emphasizing early rhythm control. Notably, both guidelines acknowledge a critical evidence gap: insufficient data exists for elderly patients, particularly those ≥85 years.

Evidence in Very Elderly Patients (≥80 Years)

Efficacy Outcomes

The most relevant recent evidence comes from three 2026 studies specifically examining octogenarians:

• The REHEALTH AF Study 3 (the highest quality prospective multicenter study) enrolled 703 patients ≥80 years, comparing 249 ablation patients to 454 conservatively managed patients. While the primary composite outcome (stroke, TIA, systemic embolism, cardiovascular events, bleeding, or death) showed no difference in unadjusted analysis (HR: 0.78, p=0.30), multivariable adjustment revealed significant benefit for ablation (adjusted HR: 0.44, p=0.029). Critically, ablation improved symptoms, quality of life, NT-proBNP levels, left atrial diameter, and preserved cognitive function (Mini-Mental State Examination) and frailty scores at 1 year.

• A Japanese multicenter study 4 of 150 very elderly patients (mean age 82.2 years) showed 2-year recurrence-free survival of 85.8% for paroxysmal AF and 63.6% for persistent AF, demonstrating reasonable efficacy even in this age group.

• A large single-center study 5 of 7,020 patients found that very elderly patients (>75 years) had higher AF recurrence at 3 years compared to younger groups (48% for persistent AF, 30% for paroxysmal AF), but ablation resulted in significant quality of life improvement regardless of age group.

Safety Profile

Periprocedural complications in very elderly patients are acceptably low but require specific attention:

• Major complication rates range from 5-12% across studies 4, 6, 5
• Most common complications:
  • Bleeding/vascular complications: 3-6% (higher than younger patients) 4, 7
  • Post-ablation heart failure: 4.7% 4
  • Pericardial effusion: increased with age 5
  • Transient renal impairment: more common in elderly 7
• No in-hospital deaths, embolic events, or esophageal complications in the dedicated very elderly cohort 4
• Importantly, periprocedural complications were not associated with increased all-cause mortality 4

Clinical Decision Algorithm for Patients ≥85 Years

When to Consider Ablation:

1. Symptomatic AF causing significant quality of life impairment (mEHRA class ≥2)
2. Paroxysmal AF preferred over persistent (better outcomes: 85.8% vs 63.6% recurrence-free survival) 4
3. Adequate functional status with preserved cognition and non-frail baseline
4. Lower NT-proBNP and preserved albumin levels (these predict better outcomes) 3
5. Patient accepts higher recurrence risk (approximately 30-48% at 2-3 years) but prioritizes symptom control and quality of life

Key Pre-Procedural Assessments:

• Frailty scoring and cognitive assessment (Mini-Mental State Examination)
• NT-proBNP and albumin levels (prognostic markers)
• Renal function (eGFR) - higher risk of transient impairment
• Vascular access assessment (higher vascular complication risk)
• Left ventricular function and volume status (post-ablation heart failure risk)

Contraindications/High-Risk Features:

• Severe frailty or advanced dementia
• Recent major bleeding or high bleeding risk
• Severe renal impairment (eGFR <30)
• Decompensated heart failure
• Limited life expectancy from comorbidities

Critical Nuances

The evidence reveals an important paradox: While AF recurrence rates are higher in very elderly patients, quality of life improvements and symptom reduction are comparable to younger patients 6, 5. This suggests that patient-reported outcomes may be more relevant than rhythm outcomes in this population.

The REHEALTH AF study 3 demonstrates that benefits emerge only after adjusting for baseline differences (NT-proBNP, albumin), indicating that careful patient selection is paramount - not all octogenarians benefit equally.

Common Pitfalls to Avoid

1. Don't dismiss ablation based solely on age - chronological age alone should not exclude patients
2. Don't expect rhythm outcomes equivalent to younger patients - set realistic expectations about 30-48% recurrence risk
3. Don't underestimate vascular complications - use ultrasound-guided access and consider smaller sheaths
4. Don't ignore volume status - post-ablation heart failure occurs in ~5% of very elderly patients
5. Don't forget anticoagulation continuation - maintain OAC regardless of rhythm outcome based on CHA₂DS₂-VASc score 1

The decision should prioritize symptom burden, quality of life goals, and functional status over achieving perfect rhythm control, as meaningful improvements in these patient-centered outcomes occur even with higher recurrence rates in very elderly patients.